Investor's Business Daily on MSN6d
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't WorriedDexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities ...
The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...
Key Takeaways DexCom received a warning letter from the Food and Drug Administration following inspections of two of its ...
DexCom Inc. closed 51.77% below its 52-week high of $142.00, which the company achieved on March 26th.
To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dexcom received a warning letter on ...
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...
Dexcom announced today that it received a warning letter from the FDA following inspections of two company facilities.
DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.
(NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
DexCom (DXCM) does not expect a material impact from the FDA’s warning letter to its manufacturing capacity or its fiscal year 2025 guidance ...
Citi raised the firm’s price target on DexCom (DXCM) to $104 from $101 and keeps a Buy rating on the shares. The firm adjusted medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback